Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +3.12% | +3.12% | -37.02% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.02% | 55.43M | C | ||
-5.17% | 180B | C+ | ||
+0.43% | 108B | C | ||
-2.00% | 68.29B | A | ||
-7.60% | 46.96B | B- | ||
+13.89% | 45.64B | B- | ||
+7.77% | 42.41B | B+ | ||
+19.67% | 31.01B | B | ||
+16.55% | 25.51B | A- | ||
-6.92% | 23.17B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APYX Stock
- Ratings Apyx Medical Corporation